Long COVID and Adverse Effects of Vaccination in a 31-year-old woman with incontinentia pigmenti

Despite multiple publications, feverishly sprouting Long Covid clinics and $1.15 billion in federal funding for the National Institutes of Health to support research, there still remains a lack of comprehensive understanding and no guidelines regarding the management of this lingering condition.

Patients with certain genetics - like inborn errors of the TLR3- and IRF7-dependent production and amplification of type I IFNs - are prone to both life-threatening COVID-19 pneumonia and adverse reactions to some vaccines - like yellow fever virus live attenuated vaccine, due to the production of autoantibodies. 

This case report describes COVID-19 infection and vaccination adverse effects in a 31-year old woman with genetic condition Incontinentia pigmenti (IP) .

This Canadian (Caucasian) woman had a severe case of COVID-19 and was hospitalized for oxygen therapy, intravenous antibiotics, and corticosteroids. 


On Day 1, she had fatigue and a sore throat. A nasopharyngeal swab on the same day tested positive for SARS-CoV-2 on polymerase chain reaction (PCR).

In Day 14, she consulted a COVID-19 clinic, complaining of fever (40.5°C), chills, myalgia, asthenia, headaches, anosmia, dysgeusia, pharyngitis, dry cough, dyspnea at speech, anorexia, dizziness, diarrhea, and facial rash. She was hospitalized and received oxygen supplementation by nasal cannula, intravenous corticotherapy, and antibiotics. She did not need intubation. She was diagnosed with bacterial pneumonia as per chest X-ray and discharged 4 days later with moxifloxacin for 7 days.

In Day 29, she consulted for relapsing cough and dyspnea. The chest X-ray showed an overall decrease in alveolar consolidation but persistence in the pulmonary bases and accentuation in the left inferior lobe. Doxycycline was started for 7 days, as well as a budesonide/formoterol inhalator.

In Day 50, she was diagnosed with acute otitis media. She complained of earache, hearing loss, sore throat, nasal congestion, rhinorrhea, headache, myalgia, and dizziness. She was subfebrile. The cough had improved somewhat. She received intranasal corticosteroids and a prescription for cefprozil antibiotic, from which she later developed a rash. Intramuscular ceftriaxone was planned but levofloxacin was tried first, given the rhinosinusitis symptoms.

In Day 70, symptoms persisted but without fever. Refractory rhinosinusitis was suspected; a non-steroidal anti-inflammatory drug was prescribed while awaiting sinus imaging.

In Day 86, a computed tomography (CT) angiography was ordered for coughing and slowly worsening dyspnea. The CT angiography showed alveolitis but no pulmonary embolism. The patient was referred to a pulmonologist. A new course of corticotherapy and antibiotics helped relieve infectious (suspected bacterial superinfection) and inflammatory symptoms.

In Month 3, symptoms persisted and now included cognitive deficits. Unable to focus attention, she quit work; academic performance dropped. 

In Month 8, side effects of a first COVID-19 vaccination on 21 April 2021 included 40°C fever and temporary exacerbation of long-haul symptoms (headaches, dizziness, nausea, chills, myalgia, cough, and dyspnea).

In Month 9, the patient was still unable to work, with persistent severe fatigue and multiple symptoms. She is still symptomatic. 

READ MORE

REFERENCE

Rheault S. Severe COVID-19 and long COVID in a 31-year-old woman with incontinentia pigmenti: A case report. SAGE Open Medical Case Reports. 2021 Nov;9:2050313X211059295.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more